D. Western Therapeutics Institute
4576
Rentracks
6045
Itamiarts
168A
Washington Hotel
4691
Migalo Holdings
5535
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 12.56%119.63B | -10.73%97.59B | 1.97%435.08B | 11.23%98.26B | -43.34%106.28B | 53.57%121.23B | 52.16%109.31B | 27.32%426.68B | -23.53%88.34B | 151.63%187.57B |
Cost of revenue | 9.52%15.9B | 10.08%14.44B | -7.46%57.6B | -14.03%15.2B | -15.60%14.52B | 2.39%14.77B | 1.34%13.12B | 12.33%62.25B | 13.61%17.68B | 33.66%17.2B |
Gross profit | 13.04%103.73B | -13.56%83.14B | 3.58%377.48B | 17.56%83.06B | -46.14%91.76B | 65.01%106.46B | 63.33%96.19B | 30.29%364.44B | -29.31%70.66B | 176.25%170.37B |
Operating expense | -1.47%50.38B | 10.94%55.03B | 4.05%224.17B | 0.53%68.49B | -1.90%51.13B | 12.78%54.94B | 6.75%49.61B | 27.17%215.43B | 36.09%68.13B | 18.68%52.12B |
Selling and administrative expenses | 5.42%25.45B | 3.67%24.04B | 1.92%99.65B | 3.33%27.99B | -0.11%24.14B | 1.06%24.33B | 3.31%23.19B | 6.54%97.78B | 7.37%27.09B | 8.41%24.17B |
-General and administrative expense | 5.42%25.45B | 3.67%24.04B | 1.92%99.65B | 3.33%27.99B | -0.11%24.14B | 1.06%24.33B | 3.31%23.19B | 6.54%97.78B | 7.37%27.09B | 8.41%24.17B |
Research and development costs | -11.04%22.62B | 17.74%29.43B | 0.24%102.64B | 8.78%30.01B | -2.50%25.43B | -15.23%22.21B | 10.95%25B | 40.27%102.39B | 11.33%27.58B | 30.11%26.08B |
Depreciation and amortization | 22.17%1.09B | 28.98%1.1B | 0.22%3.73B | 30.61%1.11B | -3.25%893M | -11.56%880M | -11.19%849M | 7.02%3.72B | -15.15%846M | 10.14%923M |
-Depreciation | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
-Amortization | 22.17%1.09B | 28.98%1.1B | 0.22%3.73B | 30.61%1.11B | -3.25%893M | -11.56%880M | -11.19%849M | 7.02%3.72B | -15.15%846M | 10.14%923M |
Other operating expenses | 46.90%1.23B | -18.18%540M | 57.60%24.34B | 18.21%15.22B | -23.12%838M | 879.82%7.62B | -5.98%660M | 239.38%15.45B | 1,736.66%12.88B | 24.86%1.09B |
Total other operating income | -90.64%16M | -16.30%77M | 58.86%6.19B | 2,085.77%5.84B | 21.28%171M | -97.17%94M | -44.24%92M | 15.22%3.9B | -83.75%267M | 4.44%141M |
Operating profit | 31.31%53.35B | -39.66%28.11B | 2.89%153.31B | 476.28%14.57B | -65.64%40.63B | 226.03%51.52B | 275.01%46.59B | 35.08%149B | -94.93%2.53B | 565.90%118.25B |
Net non-operating interest income (expenses) | 5.28%8.69B | -7.72%8.42B | -36.95%44.97B | 1.09%19.22B | -34.29%8.25B | -29.39%8.38B | -67.30%9.12B | 347.04%71.33B | 1,092.97%19.02B | 102.76%12.56B |
Non-operating interest income | -16.96%9.44B | 11.72%11.25B | -31.85%51.67B | -3.37%21.92B | -14.56%11.37B | -16.44%10.59B | -63.91%10.07B | 351.44%75.83B | 1,174.66%22.69B | 99.22%13.31B |
Non-operating interest expense | -75.89%751M | 197.59%2.84B | 48.91%6.7B | -26.46%2.7B | 317.00%3.12B | 173.76%2.21B | 3,875.00%954M | 435.08%4.5B | 1,874.73%3.67B | 54.02%747M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 26.92%62.04B | -34.43%36.53B | -10.01%198.28B | 56.86%33.8B | -62.63%48.88B | 116.50%59.9B | 38.19%55.7B | 74.50%220.33B | -58.15%21.55B | 446.13%130.81B |
Income tax | -8.42%11.58B | -53.91%6.22B | 5.22%37.71B | 93.43%-340M | -58.47%12.64B | 154.27%11.92B | 129.27%13.49B | 179.34%35.84B | -158.98%-5.18B | 387.62%30.44B |
Net income | 39.25%50.46B | -28.21%30.31B | -12.97%160.58B | 27.74%34.14B | -63.89%36.24B | 108.80%47.98B | 22.62%42.21B | 62.64%184.5B | -37.43%26.72B | 466.78%100.37B |
Net income continuous operations | 39.25%50.47B | -28.21%30.31B | -12.97%160.58B | 27.74%34.14B | -63.89%36.24B | 108.79%47.98B | 22.62%42.21B | 62.64%184.5B | -37.43%26.72B | 466.75%100.37B |
Noncontrolling interests | 47.16%-205M | 4.90%-330M | -210.23%-1.46B | -31.25%-672M | -291.92%-388M | -110.73%-47M | -17.63%-347M | 37.13%-469M | -7.34%-512M | 38.51%-99M |
Net income attributable to the company | 38.33%50.67B | -28.02%30.64B | -12.40%162.03B | 27.80%34.81B | -63.54%36.63B | 113.07%48.03B | 22.58%42.56B | 61.99%184.97B | -36.93%27.24B | 462.23%100.46B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 38.33%50.67B | -28.02%30.64B | -12.40%162.03B | 27.80%34.81B | -63.54%36.63B | 113.07%48.03B | 22.58%42.56B | 61.99%184.97B | -36.93%27.24B | 462.23%100.46B |
Gross dividend payment | ||||||||||
Basic earnings per share | 40.77%59.5637 | -25.27%36.0233 | -10.11%186.17 | 31.14%40.8733 | -62.68%42.3133 | 118.83%54.6933 | 25.57%48.2067 | 64.04%207.1033 | -34.72%31.1667 | 473.81%113.3667 |
Diluted earnings per share | 40.82%59.5637 | -25.27%36.01 | -10.11%186.1067 | 31.14%40.86 | -62.68%42.2967 | 118.81%54.6733 | 25.57%48.19 | 64.04%207.0333 | -34.73%31.1567 | 473.81%113.3267 |
Dividend per share | 0 | 0 | 18.52%53.3333 | 13.33%28.3333 | 0 | 25.00%25 | 0 | 17.39%45 | 25.00%25 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |